47. バージャー病 Buerger disease Clinical trials / Disease details
|1||ChiCTR2100048104||2021-08-01||2021-07-01||A clinical study of safety and efficacy of transcatheter intra-arterial infusion of extract of Ginkgo biloba leaves injection in the treatment of sever limb ischemia in patients with Thromboangiitis Obliterans||A clinical study of safety and efficacy of transcatheter intra-arterial infusion of extract of Ginkgo biloba leaves injection in the treatment of sever limb ischemia in patients with Thromboangiitis Obliterans||Thromboangiitis Obliterans||Treatment group:Transcatheter intra-arterial infusion of Ginkgo biloba leaves injection;Control group:Transcatheter intra-arterial infusion of heparin sodium injection;||First Clinical Center of Chinese PLA General Hospital||NULL||Pending||50||Both||Treatment group:30;Control group:30;||China|
|June 15, 2021||31/5/2021||Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease||Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease||Non-healing Wound;Thromboangiitis Obliterans||Drug: Selexipag||Actelion||NULL||Available||NULL|
|November 1, 2017||14/7/2015||Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)||A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD)||Critical Limb Ischemia;Buerger Disease;Thromboangiitis Obliterans;Atherosclerosis Obliterans||Biological: CLBS12;Drug: SOC||Caladrius Biosciences, Inc.||NULL||Recruiting||20 Years||85 Years||All||35||Phase 2||Japan|
|February 20, 2017||23/1/2017||A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease||A Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's Disease||Critical Limb Ischemia Due to Buerger's Disease||Biological: Stempeucel(R)||Stempeutics Research Pvt Ltd||NULL||Withdrawn||18 Years||65 Years||All||0||Phase 2||India|
|5||JPRN-UMIN000021374||2016/03/07||07/03/2016||Ex Vivo Expanded Erythroblast-Transplantation for patient with critical limb ischemia||Ex Vivo Expanded Erythroblast-Transplantation for patient with critical limb ischemia - EVEETA study||Peripheral Arterial Disease (PAD) , Buerger disease, and arteritis associated with collagen diseases (Fontaines stage: III and IV)||1)Autologous Bone Marrow Collection: 40 to 60 ml of bone marrow is collected from iliaccrest under local anaesthesia 14 days before the implantation.|
2)Ex vivo expanded immature erythroblasts from autologous bone marrow cells : All procedures are enforced by exclusive
technical exparts along the approved protocols in GMP-grade Cell Processing Room established in Bioscience Medical Research Center, Niigata University Medical and Dental Hospital. Mononuclear cells separated from the bone marrow are incubated in a suspension culture in the presence of rh Flt-ligand, rh SCF, rh Thrombopoietin, and culture supplements for 7 days to expand myeloid progenitors. Harvested and washed cells are further cultured in the presence of rh SCF, rh IGF-I, rh Erythropoietin, and culture supplements for additional 7 days to expand immature erythroblasts and macrophages. Cultured cells are finally harvested, washed, suspended in 50 ml of autologous platelet rich plasma, and transferred from the bio clean room to bedside.
3)Transplantation of cultured cell: Aliquots of the 50 ml of cell suspension are intramuscularly injected in 100 points of the ischaemic limb. Daily intramuscular injection of 6000 IU of rh erythropoietin in the same loci follows from day 0 for consecutive 5 days.
|EVEETA Study Group||NULL||Complete: follow-up complete||20years-old||80years-old||Male and Female||11||Not selected||Japan|
|January 2012||27/11/2011||A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease||A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease||Critical Limb Ischemia;Buerger's Disease||Biological: Allogeneic Mesenchymal Stem Cells||Stempeutics Research Pvt Ltd||NULL||Completed||18 Years||65 Years||Both||90||Phase 2||India|
|7||JPRN-UMIN000005227||2011/03/01||09/03/2011||Transplantation of autologous and G-CSF mobilized mononuclear cells in patients with critical limb ischemia (CLI)||CLI (Atherosclerotic PAD/Buerger disease )||Subcutaneous administration of G-CSF, Harvest and implantation of PB-MNC||Regenerative Medicine Unit, Division of Vascular Regeneration Therapy, Institute of Biomedical Research and Innovation (IBRI)||NULL||Complete: follow-up complete||20years-old||80years-old||Male and Female||5||Not selected||Japan|
|January 2009||5/10/2011||Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan||Treatment of Thromboangiitis Obliterans (Buerger's Disease) With Bosentan||Thromboangiitis Obliterans||Drug: Bosentan||Hospital Universitario Getafe||NULL||Completed||18 Years||65 Years||Both||12||N/A||Spain|
|December 2007||17/2/2011||Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease||Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease||Buerger's Disease||Biological: RNL-Vascostem®||R-Bio||NULL||Completed||20 Years||80 Years||All||15||N/A||Korea, Republic of|